Type 2 Diabetes Clinical Trial
Official title:
The Smart-phone as a Physical Fitness Monitor on a Population Level - Validity and Sensitivity and Improtance of Individual Motivation for Doing Interval Walking With the InterWalk Application
| Verified date | October 2017 |
| Source | University of Copenhagen |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Low physical fitness may cause several life style related diseases e.g. cardiovascular
disease, cancer and type 2 diabetes. It is important to develop reliable methods for
measurement which can be used to follow the development of the physical shape both on an
individual level and on at population level.
Associated with the development of new training method known as Interval Walking we developed
an application for smartphones. The use of the application InterWalk was meant to increase
physical activity in patients with type 2 diabetes. The application should both be able to,
1) be a personal trainer when doing interval walking, and 2) measure the individual physical
fitness performed as a walking test. The latter function was developed to make the training
more personal and individal adapted, so that the training was neither too hard or too easy.
It is necessary to test the walking test against a golden standard for measuring physical
fitness and that the test in the application is able to measure and register changes in
physical fitness.
Our hypothesis is that the individual test, in the InterWalk Application is reliable and able
to register changes in physical fitness in patients with type 2 diabetes. The purpose of this
project is investigate the reliability of a smartphone-based test of physical fitness, and to
investigate whether the test is able to register changes in physical fitness during the
project time (3 month). A secondary aim is to investigate whether individual support during
the training period, affect the individual effort and time of interval walking per week.
| Status | Completed |
| Enrollment | 37 |
| Est. completion date | December 2014 |
| Est. primary completion date | December 2014 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 30 Years to 80 Years |
| Eligibility |
Inclusion Criteria: - Type 2 diabetes, age 30-80 y, BMI >18 but <40 kg/m2 and confirmed T2D diagnose Exclusion Criteria: - Pregnancy, smoking, contraindication to increased levels of physical activity, insulin dependence, evidence of thyroid, liver, lung, heart or kidney disease |
| Country | Name | City | State |
|---|---|---|---|
| Denmark | Center of Inflammation and Metabolism | Copenhagen |
| Lead Sponsor | Collaborator |
|---|---|
| Laura Staun Valentiner | Rigshospitalet, Denmark |
Denmark,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The primary outcome is amount of time duing interval walking (in minuts) with InterWalk per week after 3 month | up to 3 months after enrollment | ||
| Secondary | Frequency of Interval walking with InterWalk | 3 months after enrollment | ||
| Secondary | Quality of data with VO2-peek test in the InterWalk Application | quantity of minuts with high and low intervals after 3 month | 3 months after enrollment | |
| Secondary | validation of InterWalk, VO2-peek test | 3 months after enrollment | ||
| Secondary | VO2-peek test in the InterWalk Application | 3 months after enrollment |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |